Treatment options for prostate cancer: Evaluating the evidence

被引:0
|
作者
Bhatnagar, V
Kaplan, RM
机构
[1] Vet Affairs San Diego Healthcare Syst, Hlth Serv Res & Dev, La Jolla, CA 92161 USA
[2] Univ Calif San Diego, Dept Family & Prevent Med, Sch Med, San Diego, CA 92103 USA
[3] Univ Calif Los Angeles, Sch Publ Hlth, Hlth Serv, Los Angeles, CA 90024 USA
[4] RAND Corp, Santa Monica, CA 90406 USA
关键词
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Controversy surrounds the management options for localized prostate cancer-conservative management, prostatectomy, and radiation. Choosing among these options is difficult because of long-term side effects that include sexual, urinary, and bowel dysfunction. Some recent studies suggest that patients who have chosen treatment (i.e., radical prostatectomy or radiation) have longer disease-free survival compared with patients who have chosen conservative management (i.e., watchful waiting). However, several biases may artificially enhance the perceived value of treatment and make the interpretation of studies on treatment outcomes difficult. Sources of bias include lead time, length time, and patient selection. Because of the uncertain efficacy of management options and the risk of long-term treatment complications, family physicians need to engage their patients in the decision-making process. Copyright (c) 2005 American Academy of Family Physicians.
引用
收藏
页码:1915 / 1922
页数:8
相关论文
共 50 条
  • [41] Novel options for the treatment of castration-resistant prostate cancer
    Carsten-H. Ohlmann
    Axel S. Merseburger
    Henrik Suttmann
    David Schilling
    Lutz Trojan
    Carsten Kempkensteffen
    Stefan Corvin
    Michael J. Mathers
    Patrick J. Bastian
    World Journal of Urology, 2012, 30 : 495 - 503
  • [42] Comparison of four Treatment Options for low risk Prostate Cancer
    Rexer, H.
    Bussar-Maatz, R.
    UROLOGE, 2015, 54 (05): : 723 - 725
  • [43] New Treatment Options in Castration-Resistant Prostate Cancer
    Armstrong, Andrew J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (5.5): : 690 - 693
  • [44] Inhibition of Angiogenesis: Treatment Options for Patients with Metastatic Prostate Cancer
    William D. Figg
    Erwin A. Kruger
    Douglas K. Price
    Sonia Kim
    William D. Dahut
    Investigational New Drugs, 2002, 20 : 183 - 194
  • [45] PROSTATE CANCER RECURRENCE AFTER FOCAL THERAPY: TREATMENT OPTIONS
    Hamid, S.
    Guillaumier, S.
    Shah, T.
    Arya, M.
    Ahmed, H. U.
    ARCHIVOS ESPANOLES DE UROLOGIA, 2016, 69 (06): : 375 - 383
  • [46] Palliative and supportive treatment options in patients with advanced prostate cancer
    Maurer, T.
    Retz, M.
    Gschwend, J. E.
    UROLOGE, 2007, 46 (01): : 30 - 35
  • [47] CONCERN GROWS OVER PROSTATE-CANCER TREATMENT OPTIONS
    PARKINS, T
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (12) : 897 - 898
  • [48] Treatment options for metastatic hormone-sensitive prostate cancer
    Kostos, Louise
    Murphy, Declan G.
    LANCET ONCOLOGY, 2022, 23 (10): : 1234 - 1235
  • [49] Distribution of prostate cancer treatment options in newly diagnosed patients
    Ham, Yeji
    Nzenza, Tatenda
    Weerasinghe, Arosha
    Bolton, Damien
    Lawrentschuk, Nathan
    Sengupta, Shomik
    BJU INTERNATIONAL, 2018, 122 : 5 - 6
  • [50] Distribution of Prostate Cancer Treatment Options in Newly Diagnosed Patients
    Ham, Yeji
    Weerasinghe, Arosha
    Nzenza, Tatenda
    Bolton, Damien
    Lawrentschuk, Nathan
    Sengupta, Shomik
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 35 - 35